We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
CarGurus Inc is a company that acts as an online automotive marketplace connecting buyers and sellers of new and used cars. The company provides three types of marketplace Listing products, Restricted Listings, and Enhanced or Featured Listing through which it offers real-time and historical data an... CarGurus Inc is a company that acts as an online automotive marketplace connecting buyers and sellers of new and used cars. The company provides three types of marketplace Listing products, Restricted Listings, and Enhanced or Featured Listing through which it offers real-time and historical data analyzing the connections and pricing analysis. It also provides all dealers with a web widget to place Deal Rating Badges, which show deal rating. The listing platforms offer auto manufacturers and others to buy advertising on the company's site and target consumers based on the make, model, and zip code of the cars. The company operates through two geographical segments namely United States and the International. Most of the company's revenue comes from the United States. Show more
DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to...
Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first half of 2023 Reaffirms ANTHIM as an important medical countermeasure in the U.S...
DURHAM, N.C., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to...
DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to...
Designed for rapid “plug and play” programming and stockpiling against emerging infectious agents and viral mutations Emergence of Omicron and other COVID-19 variants underscores the need for a...
DURHAM, N.C., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), today provided strategic, financial, and operational updates for the third quarter ended September...
DURHAM, N.C., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to...
DURHAM, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the...
DURHAM, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the...
DURHAM, N.C., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to...
| Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 2.23 | 9.71254355401 | 22.96 | 26.19 | 21.65 | 962453 | 22.44351865 | CS |
| 4 | -0.54 | -2.09871745045 | 25.73 | 26.83 | 21.65 | 703099 | 24.4054929 | CS |
| 12 | 1.41 | 5.92935239697 | 23.78 | 26.9 | 21.65 | 753474 | 24.74233053 | CS |
| 26 | 1.54 | 6.51162790698 | 23.65 | 26.9 | 21.18 | 951264 | 23.58472886 | CS |
| 52 | 5.95 | 30.9251559252 | 19.24 | 26.9 | 16.705 | 943100 | 21.76879375 | CS |
| 156 | -5.63 | -18.2673588579 | 30.82 | 50.03 | 9.1418 | 1193937 | 23.45003118 | CS |
| 260 | -8.3 | -24.7835174679 | 33.49 | 50.03 | 9.1418 | 1244494 | 24.86188748 | CS |
Monksdream
5 months ago
jackieadams75
5 years ago
ofthegreenes
7 years ago
mick
7 years ago
mick
7 years ago
mick
7 years ago
mick
7 years ago
mick
7 years ago
TheFinalCD
7 years ago
TheFinalCD
7 years ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
